Analyzing prognosis and risk factors for acute kidney injury
Analysis for Prognosis and Risk Factors for Acute Kidney Injury: Multi-center Cohort Study
This study is testing how severe acute kidney injury affects adults' long-term health and financial well-being by looking at their medical records and blood test results.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 320000 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06898944 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze the diagnosis and prognosis of acute kidney injury (AKI) by assessing its severity and defining long-term clinical and socioeconomic outcomes. It involves adults aged 20 years or older who visited participating medical centers and underwent at least two blood tests for serum creatinine within a week. The study population includes an AKI group, defined by specific diagnostic criteria, and a matched control group based on age, sex, and baseline kidney function. Various clinical, laboratory, and hospitalization records will be collected and analyzed to understand the implications of AKI.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 20 years old who have experienced acute kidney injury as defined by the KDIGO guidelines.
Not a fit: Patients under 20 years old or those with pre-existing end-stage kidney disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding of AKI and lead to better management and outcomes for affected patients.
How similar studies have performed: Other studies have shown success in analyzing AKI prognosis, making this approach both relevant and supported by existing literature.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults over 20 years old who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021 * The AKI group is defined as individuals meeting the AKI diagnostic criteria of the KDIGO Guideline (an increase in serum creatinine of ≥0.3 mg/dL or ≥1.5 times the baseline level) is enrolled. * The Control Group is defined as individuals from the study population who do not meet the AKI criteria and are matched 1:1 based on age, sex, year of visit, and baseline renal function. Exclusion Criteria: * Individuals under 20 years old * Individuals who did not undergo serum creatinine tests meeting the criteria * Individuals with pre-existing end-stage kidney disease (ESKD) who have undergone dialysis or kidney transplantation
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Dong Ki Kim, M.D. Ph.D. — Department of Internal Medicine, Seoul National University Hospital
- Study coordinator: Sehoon Park, M.D. Ph.D.
- Email: mailofsehoon@gmail.com
- Phone: +82-02-2072-4070
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.